Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.9K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.9K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

603
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
603

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

'Genetic modelling of triglyceride-rich lipoprotein/remnant lowering mimics APOC3-silencing and predicts clinically relevant coronary heart disease event reductions': author's response.

European journal of preventive cardiology·2025
Same author

Genetic modelling of triglyceride-rich lipoprotein/remnant lowering mimics APOC3-silencing and predicts clinically relevant coronary heart disease event reductions.

European journal of preventive cardiology·2025
Same author

Redefining the association of triglycerides with all-cause and Cardiovascular Disease Mortality in the Chinese population: a nationwide, population-based, prospective cohort study of 3.8 million Chinese adults.

The Lancet regional health. Western Pacific·2025
Same author

Great debate: Plasma triglycerides are an important causal factor and therapeutic target for atherosclerotic cardiovascular disease.

European heart journal·2025
Same author

Addressing residual risk beyond statin therapy: New targets in the management of dyslipidaemias-A report from the European Society of Cardiology Cardiovascular Round Table.

Journal of clinical lipidology·2024
Same author

Prediction of individual lifetime cardiovascular risk and potential treatment benefit: development and recalibration of the LIFE-CVD2 model to four European risk regions.

European journal of preventive cardiology·2024

Related Experiment Video

Updated: Apr 15, 2026

Stimulation of Vascular Endothelial Cells Using Neutrophil Extracellular Traps in the Presence of Low-Density Lipoprotein
07:26

Stimulation of Vascular Endothelial Cells Using Neutrophil Extracellular Traps in the Presence of Low-Density Lipoprotein

Published on: August 12, 2025

848

Did we IMPROVE-IT: thoughts on LDL targeting post-trial?

Chris Packard1, Tanya Stezhka

  • 1University of Glasgow, Institute of Cardiovascular and Medical Sciences, Clinical Research Facility, Tennent Building, Western Infirmary, Church Street, Glasgow, G12, UK.

Expert Review of Cardiovascular Therapy
|April 14, 2015
PubMed
Summary

The IMPROVE-IT trial shows adding ezetimibe to simvastatin significantly reduces cardiovascular events in acute coronary syndrome patients. Lowering LDL cholesterol with this combination therapy provides long-term benefits.

Area of Science:

  • Cardiovascular Medicine
  • Clinical Trials
  • Pharmacology

Background:

  • The IMPROVE-IT trial investigated the long-term effects of adding ezetimibe to simvastatin.

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.3K
Author Spotlight: Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment
07:12

Author Spotlight: Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment

Published on: June 2, 2023

9.0K

Related Experiment Videos

Last Updated: Apr 15, 2026

Stimulation of Vascular Endothelial Cells Using Neutrophil Extracellular Traps in the Presence of Low-Density Lipoprotein
07:26

Stimulation of Vascular Endothelial Cells Using Neutrophil Extracellular Traps in the Presence of Low-Density Lipoprotein

Published on: August 12, 2025

848
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.3K
Author Spotlight: Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment
07:12

Author Spotlight: Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment

Published on: June 2, 2023

9.0K
  • Acute coronary syndrome (ACS) patients are at high risk for recurrent cardiovascular events.
  • Understanding the role of cholesterol-lowering agents beyond statins is crucial.